Epilepsy is primarily treated symptomatically - that is, the majority of the available medications aim to suppress seizures ...

This deletion mutation, a type of mutation where a section of DNA is missing, not only explains the peculiarity of ginger genetics, but also reveals an entirely new mechanism for promoting orange ...

Advanced Materials and Catalysis Group, Center of Chemistry for Frontier Technologies, State Key Laboratory of Clean Energy Utilization, Institute of Catalysis, Department of Chemistry, Zhejiang ...

"This preliminary work opens exciting avenues for future research to clarify the underlying mechanisms and to develop new improved therapies focusing on increasing energy expenditure for long-term ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and chemotherapy reduces the risk of death by 17% in HER2-positive early breast cancer.

(RTTNews) - CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors. CytoDyn analyzed ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta ® (pertuzumab), Herceptin ® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...

1 After ten years, the risk of death was reduced by 17% for people treated with Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta ® (pertuzumab) to Herceptin ® (trastuzumab) and chemotherapy ...